User login
Key clinical point: Induction therapy with tofacitinib or prednisone significantly increased serum lipid levels in patients with inflammatory bowel disease (IBD), whereas no changes were observed with immunomodulators or biologics.
Major finding: At 10 weeks, the total cholesterol, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol levels increased significantly in patients who initiated tofacitinib (+20%, +25%, and +26%, respectively; all P < .05) or prednisone (+26%, +31%, and +12%, respectively; all P < .05) therapy. The changes in lipid levels were not significant with other biologics or immunomodulators.
Study details: This was a prospective study that included 198 patients with ulcerative colitis (n = 61), Crohn’s disease (n = 137), or unclassified IBD (n = 8) who initiated prednisone, thiopurine, methotrexate, an anti-tumor necrosis factor alpha agent, ustekinumab, vedolizumab, or tofacitinib.
Disclosures: This study did not receive any funding. AC de Vries and CJ van der Woude declared receiving research funding and serving as advisory board members for various sources.
Source: Sleutjes JAM et al. Lipid changes after induction therapy in patients with inflammatory bowel disease: Effect of different drug classes and inflammation. Inflamm Bowel Dis. 2022 (May 19). Doi: 10.1093/ibd/izac100
Key clinical point: Induction therapy with tofacitinib or prednisone significantly increased serum lipid levels in patients with inflammatory bowel disease (IBD), whereas no changes were observed with immunomodulators or biologics.
Major finding: At 10 weeks, the total cholesterol, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol levels increased significantly in patients who initiated tofacitinib (+20%, +25%, and +26%, respectively; all P < .05) or prednisone (+26%, +31%, and +12%, respectively; all P < .05) therapy. The changes in lipid levels were not significant with other biologics or immunomodulators.
Study details: This was a prospective study that included 198 patients with ulcerative colitis (n = 61), Crohn’s disease (n = 137), or unclassified IBD (n = 8) who initiated prednisone, thiopurine, methotrexate, an anti-tumor necrosis factor alpha agent, ustekinumab, vedolizumab, or tofacitinib.
Disclosures: This study did not receive any funding. AC de Vries and CJ van der Woude declared receiving research funding and serving as advisory board members for various sources.
Source: Sleutjes JAM et al. Lipid changes after induction therapy in patients with inflammatory bowel disease: Effect of different drug classes and inflammation. Inflamm Bowel Dis. 2022 (May 19). Doi: 10.1093/ibd/izac100
Key clinical point: Induction therapy with tofacitinib or prednisone significantly increased serum lipid levels in patients with inflammatory bowel disease (IBD), whereas no changes were observed with immunomodulators or biologics.
Major finding: At 10 weeks, the total cholesterol, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol levels increased significantly in patients who initiated tofacitinib (+20%, +25%, and +26%, respectively; all P < .05) or prednisone (+26%, +31%, and +12%, respectively; all P < .05) therapy. The changes in lipid levels were not significant with other biologics or immunomodulators.
Study details: This was a prospective study that included 198 patients with ulcerative colitis (n = 61), Crohn’s disease (n = 137), or unclassified IBD (n = 8) who initiated prednisone, thiopurine, methotrexate, an anti-tumor necrosis factor alpha agent, ustekinumab, vedolizumab, or tofacitinib.
Disclosures: This study did not receive any funding. AC de Vries and CJ van der Woude declared receiving research funding and serving as advisory board members for various sources.
Source: Sleutjes JAM et al. Lipid changes after induction therapy in patients with inflammatory bowel disease: Effect of different drug classes and inflammation. Inflamm Bowel Dis. 2022 (May 19). Doi: 10.1093/ibd/izac100